30 closest matches · ranked by relevance
End Stage Renal Disease
Primary: Number of Patients That Underwent Transplantation — 32 Participants
End Stage Renal Disease (ESRD)
Primary: Number of Participants With Serious Infectious Complications Following Transplantation — 2 participants
Highly-sensitized Kidney Transplant Recipients
Primary: The Number of Polyoma BK Viremia Patients — 5 Participants
HLA Sensitization
Primary: Number of Living Donor Transplant Candidates That Are Transplanted — 19 participants
End Stage Renal Disease
Primary: Number of Participants With Treatment-related Adverse Events and Treatment Failure — 2; 2; 1; 1 Participants
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
End Stage Renal Disease
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…
Renal Disease
Primary: Number of Participants With Allograft Rejection — 7 Participants
Kidney Failure, Chronic · Diabetic Nephropathies · Glomerulonephritis, IGA
Primary: The Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months Post Rituximab Infusion. — 6 Participants
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
Kidney Transplant Rejection
Primary: Number of Participants With Biopsy-proven Acute Rejection — 1; 2 Participants
Immunosuppression · Kidney Transplantation · Graft Rejection
Primary: The Ability to Withdraw Immunosuppression as Above 24 Months Post-transplant — 6 Participants
Kidney Failure, Chronic · Diabetic Nephropathies · Glomerulonephritis, IGA
Primary: The Number of Subjects With a 10% Decrease in PRA Level at Month 8. — 9 Participant
Kidney Failure, Chronic
Primary: Number of Patients With Crossmatch Conversion (Positive to Negative) — 17; 2 Patients
Other Complication of Kidney Transplant · Renal Transplant Rejection
Primary: Cases of Kidney Transplant Patients With DSA — 0; 0 Participants
Kidney Diseases · End Stage Renal Disease
Primary: Efficacy of Ixazomib: Percentage of Participants With > 20 Percent Decline in Calculated Panel Reactive Antibody (cPRA) — 0 Participants
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Kidney Transplantation
Primary: Response to Bortezomib Monotherapy — 0; 0; 0; 1 participants
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
Stage V Chronic Kidney Disease
Primary: Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation — 7; 73; 3; 4 Participants — p=< 0.001
Malignant Diseases · Non-malignant Diseases
Primary: Number of Patients With Severe (Grade III/IV) Acute Graft vs Host Disease (GVHD) — 0 Participants
Blood Cancer · Leukemia · Graft Versus Host Disease
Primary: Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and…
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Anemia, Aplastic · Amegakaryocytic Thrombocytopenia · Diamond-Blackfan Anemia
Primary: Treatment Failures
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Lung Transplant Rejection · Antibody-mediated Rejection
Primary: Donor-specific HLA Antibodies, Re-transplantation, or Death — 0; 5; 3; 3 participants
Liver Transplant · Liver Transplantation
Primary: The Percent of Participants Who Achieve Operational Tolerance 52 Weeks After Completion of Immunosuppression Withdrawal. — 16.4 Percent of Participants
Hemophagocytic Lymphohistiocytosis · X-Linked Lymphoproliferative Disorders · Chediak-Higashi Syndrome
Primary: Number of Subjects With Mixed Chimerism — 3; 8; 4 participants